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University, Morgantown, WA; West Virginia Clinical and Translational Institute, Morgantown, WV.
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OVERVIEW

Author Manuscript

In recent years, there has been a revolutionary expansion in technologic advances and therapeutic
innovations in cancer medicine. Cancer diagnostics has begun to move away from a sole
dependence on direct tumor tissue biopsy for cancer detection, diagnosis, and treatment
monitoring. The need for improvement in molecular cancer diagnostics has never been more
important, with not only the advent of cancer genomics and genomics-guided precision medicine
but also the recent arrival of cancer immunotherapies. Owing to the practical limitations and risks
associated with tissue-based biopsy diagnostics, novel noninvasive cancer diagnostics platforms
have continued to evolve and expand in recent years. Examples of these platforms include the
liquid biopsy, which is used to interrogate ctDNA or circulating tumor cells, proteomics,
metabolomics, and exosomes; the urine biopsy, which is used to assay ctDNAs; saliva and stool
biopsies, which are used for molecular genomics assays; and the breath biopsy, which measures
volatile organic compounds. These next-generation noninvasive molecular diagnostics assays
beyond tissues fundamentally transform the potential utilities of cancer diagnostics to enable
repeat, prospective, and serial longitudinal “biopsies” to monitor disease response resistance and
progression on therapies. Moreover, they allow continual interrogation and molecular in-depth
analysis of the evolving tumor’s pan-canceromics under therapeutic stress. These technological
and diagnostic advances have already brought about paradigm-changing next-generation cancer
therapeutic strategies to enhance overall treatment efficacies. This article reviews the key
noninvasive next-generation molecular diagnostics platforms beyond tissues, with emphasis on
clinical utilities and applications.

Author Manuscript

In recent years, there has been a revolutionary expansion in technologic advances in cancer
medicine. For decades, cancer diagnostics has been predominantly dependent on direct
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tumor tissue biopsy for histologic and pathologic analysis. Modern state-of-the-art nextgeneration DNA sequencing and genomics bioinformatics analysis have brought forth a new
paradigm shift in recent years from microscopic levels of histologic diagnostics to molecular
genomics levels of cancer molecular diagnostics. Coupled with the revolution in remarkable
drug development innovation and efficiency in the new era of small molecule chemistry and
therapeutics, these exciting new trends engendered the birth of genomics-guided
personalized cancer therapy, with examples of inhibitors adopted in the treatment of EGFRmutant,1 and ΑLK-fusion lung cancer,2 and BRAF-mutant melanoma,3 among others.
Nonetheless, with the current widespread clinical applications of genomics-matching
personalized cancer therapy, it has also become increasingly evident that the need to obtain a
large amount of tumor tissue through invasive tumor-needle or surgical biopsy procedures is
self-defeating. The risks and inconvenience of such invasive procedures limit the scope of
molecular-genomic profiling achievable in the tissues. This problem is substantially
compounded by the arrival of cancer immunotherapies in the last few years, for which the
need for diagnostics and predictive biomarkers is paramount. As a result, many research
studies have been emphasized in achieving next-generation novel cancer diagnostics beyond
the use of tumor tissues obtained from primary or metastatic tumor sites. These include the
innovative utility of various body fluids or substrates from different body compartments that
allow more noninvasive and low-risk access. In this article, we provide a broad overview of
the emerging or well-developed technologic platforms (Fig. 1) for these novel cancer
diagnostic applications.

LIQUID BIOPSY
Cellular Compartment

Author Manuscript
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Circulating tumor cells.—Circulating tumor cells (CTCs) are cells that have
disseminated away from the primary tumor or secondarily from metastatic sites and further
deposited into the circulatory bloodstream.4–6 Previous studies suggested that epithelial-tomesenchymal transition (EMT) may be involved in this active mobilization and
dissemination of tumor cells. increasing their plasticity and trans-migratory potential.7,8
EMT is thought to assist tumor cells in their active intravasation mechanisms into the
vasculature. During this process of dissemination, epithelial tumor cells lose their cell-cell
contact and apical-basal polarity to gain a more elongated cell phenotype associated with
enhanced cell motility and invasiveness.9,10 Interestingly, recent evidence also suggests that
platelets adhering to CTCs in the circulation could induce EMT itself.11 The EMT activation
process leading to a more motile and invasive phenotype is also induced by the milieu of the
tumoral microenvironmental make-up.12 EMT-triggering signals include transforming
growth factor β secreted by the activating platelets,11 integrin-macrophage Interactions
through epidermal growth factor supply,13 and proinflammatory cytokines secreted by
fibroblasts.4,14
Circulating tumor cell enrichment and detection.—Because CTCs clearly represent
the tumor cell populations responsible for and involved in the process of metastasis, which is
the leading cause of cancer morbidity and mortality, there has been intense interest in
enhancing the ability to enrich, capture, detect, isolate, and characterize CTCs. Nonetheless,
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there are numerous intrinsic challenges in this approach. The size dimension of CTCs varies
depending on the different cancer types of origin; for example, small cell lung cancer
(SCLC) cells are only approximately 10 μm in diameter, but prostate CTCs can be larger
than 100 μm.15 Moreover, CTCs are extremely rare, and the sensitivity of CTC detection in
patient blood is highly dependent on detection methods. No validated formula is available to
estimate the true number of CTCs for each patient with cancer, or even for any cancer type.
Importantly, how to define what constitutes a CTC and whether even the detected CTCs are
functionally important is also quite controversial and challenging. It was recently suggested
that even EMT in the CTCs belongs to a continuum rather than a binary phenotype.

Author Manuscript

CellSearch (Menarini Silicon Blosystems Inc., San Diego, CA) is currently the only U.S.
Food and Drug Administration-approved detection system for enrichment, detection, and
enumeration of CTCs, based on the epithelium-specific cell adhesion molecule (EpCAM)
expressed on the surfaces of epithelium-derived CTCs. Allard et al16 reported average
recovery sensitivity of 85% or greater. Beyond enumeration, which obviously has limitations
in the underlying biologic information and applications to induce wide clinical adoption,
newer approaches to achieve CTC capture have been developed, including microfluidic
platforms such as the CTC-Chip, in which CTCs interact with EpCAM-coated micro-posts
under laminar flow conditions.17 However, despite a more streamlined workflow, this
positive-selection capture platform and other similar available platforms still depend on
EpCAM detection, which may not best define a bona fide CTC.18–21

Author Manuscript

To overcome the challenge of CTCs possessing the EMT phenotype and potentially having
low to negative EpCAM expression, a number of studies have pioneered the use of EpCAMIndependent enrichment strategies. Examples include using CD45-conjugated magnetic
beads to enrich CTCs through leukocyte depletion by the EasySepR bi-antibody leukocyte
depletion kit (STEMCELL Technologies, Vancouver, BC, Canada) in an negative
electromagnetic separation.22 Another novel platform that has emerged recently is the
VTX-1 liquid biopsy system (Vortex Biosciences, Menlo Park, CA), which is capable of
capturing and isolating CTCs that may remain viable and requires no preprocessing or
labeling of blood samples. Sollier et al23 reported using this system to extract and enumerate
CTCs from the blood of patients with lung cancer (23–317 CTCs/7.5 mL) and breast cancer
(25–51 CTCs/7.5 mL) and lung cancer.

Author Manuscript

By using these new technologies to fully interrogate CTCs molecularly or genomically, one
could further unleash the power of the molecular diagnostics platform with multitudes of
possible clinical applications. Fan et al24 demonstrated high sensitivity and specificity in
hepatocellular cancer diagnosis using CTCs and could apply them asa real-time parameter
for risk prediction and treatment monitoring, enabling early decision making to tailor
effective antitumor strategies. Miyamoto et al25 used microfluidic cell enrichment to
establish a sensitive and high-throughput strategy for analyzing prostate CTCs and reported
Its potential utility in guiding treatment selection in both metastatic and localized prostate
cancer. Wang et al26 combined a postsurgical quantity of small triploid CTCs (five or more
cells per 6 mL blood) and multiploid (pentasomy of eight or greater) circulating tumor stem
cells (CTSCs) or circulating tumor microembolis (CTMs; either one or more than one),
which correlated with poor prognosis for patients with hepatocellular carcinoma and helped
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predict recurrence. Ilié et al27 collected peripheral blood samples with CTCs and circulating
white blood cells from 106 patients with advanced non-small cell lung cancer (NSCLC). The
authors demonstrated that PD-L1 status in CTCs and circulating white blood cells correlates
with PD-L1 status in tumor tissue, revealing the potential of CTC assessment as a
noninvasive real-time biopsy to evaluate PD-L1 expression for patients with advanced-stage
NSCLC.27

Author Manuscript

A recent prospective study to evaluate CTC profiles in NSCLC molecular subgroups
enrolled 125 patients with stage NIB to IV NSCLC without treatment.28 Of these patients,
51 (40.8%) were found to betotal CTC-positive and 26 (20.8%) were vimentin CTC-positive
at baseline. Multivariate analysis showed that patients with five or more total CTCs had
reduced overall survival compared with patients with fewer than five total CTCs. The
baseline presence of five or more total CTCs was validated to be correlated with a poor
prognosis. CTCs from patients with EGFR-mutant NSCLC expressed EMT characteristics
not seen in CTCs from patients with KRAS-mutant adenocarcinoma.
Ilie et al29 adopted the CellSearch and ISET (Rarecells, Paris, France) technologies to enrich
patients with advanced stage lll/IV NSCLC and to interrogate MET biomarker expression.
With CellSearch, CTCs were found for 83 of 256 patients (32%). With ISET, CTCs were
found for 80 of 106 patients (75%). MET expression was found on ISET CTCs in 72% of
cases, whereas MET expression on matched-patient tissue was positive for 65% of patients
(93% concordance). Quantitative MET expression analysis using H-scores revealed a strong
correlation of MET expression between tissue and CTCs (Spearman correlation, 0.93). The
study results identified CTCs as a potential method for noninvasive, real-time biopsy to
determine the MET status of patients entering clinical trials.29

Author Manuscript

Real-time prospective CTC measurement is an attractive platform to monitor disease
treatment response and progression. In a recent study. Pailler et al30 collected blood samples
at baseline pretreatment and 2 months after crizotinib treatment from 39 patients with ALKfusion NSCLC undergoing crizotinib therapy. The results suggested that the dynamic change
in CTC numbers with ALK-copy number gain may be a predictive biomarker for crizotinib
efficacy, lending further support for serial molecular analysis of CTCs as a promising
method for real-time therapy monitoring and clinical outcome prediction for these patient
populations.30
Soluble Compartment

Author Manuscript

ctDNA.—Both cell-free DNA (cfDNA) and ctDNA originating from normal and cancer
cells can be identified and isolated in the peripheral blood.4–31 The major fragment size of
cfDNA is approximately 170 base pairs, which corresponds well to the nucleosomal
fragments resulting from the process of cellular apoptosis.32 ctDNA is a fraction of cfDNA
that originates from primary, metastatic tumors in the body or from CTCs themselves. As a
result, ctDNA fragments are found to contain tumor-specific somatic alterations and
epigenetic aberrations in the blood. The estimated half-life of free DNA in the circulation is
reported to be between 16 minutes and 2.5 hours.31,33 Nonmutant cfDNA molecules are
longer than ctDNA in plasma.34,35
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The detection of ctDNA for molecular diagnostics is fundamentally challenged by the large
excess of background wildtype DNA present in the circulation. Tumor-specific markers that
allow the distinction of tumor-derived cfDNA as ctDNA from the wild-type DNA fraction
can include mutations, indels, gene copy number changes, chromosomal rearrangements, or
aberrant methylation.36 Levels of wild-type DNA can be released during serum preparation;
hence, plasma is preferred as the biologic material for molecular extraction and assays.
Chromosomal rearrangements can be detected with high sensitivity using polymerase chain
reaction (PCR) but require genome-wide sequencing of the primary tumor to find potential
target aberrations.37 Copy number changes detected by low-coverage genome sequencing
have been applied to detect ctDNA without knowledge about the primary tumor genome, but
this approach requires relatively high ctDNA concentrations for a successful detection.38
Point mutations and indels (short insertions and deletions) are the most frequently used
diagnostic ctDNA markers.31 Studies have shown reasonably good concordance of tumoral
genomic alterations in ctDNA compared with that detected from tumor tissue genomic
assays.39 However, there are also studies that highlight the high specificity of ctDNA
mutation detection but low sensitivity compared with tumor tissue mutation assays,
suggesting that negative ctDNA assays might need to be confirmed with tumor tissue DNA
mutation detection, as in the case of the EGFR-T790M assay.40–43

Author Manuscript
Author Manuscript

Liquid biopsy techniques for assaying ctDNAs for genetic/genomic marker alterations have
been increasingly applied in recent years to longitudinally monitor patients with cancer,44–48
especially those with initial actionable genomic mutations/alterations who are receiving
specific cancer therapies. To detect ALK fusions and ALK mutations and track the evolution
of drug resistance during treatment, Dagogo-Jack et al45 procured blood plasma from 22
patients who had ALK-positive disease with acquired resistance to ALK tyrosine kinase
inhibitors (TKIs). The correlation between plasma ALK mutations and response to distinct
ALK precision inhibitors brought attention to the potential for liquid ctDNA biopsy analysis
to guide ALK precision therapy decisions.45 In another recent study, Guibert et al46
collected 168 specimens from a total of 46 patients with NSCLC and adopted enhanced
tagged amplicon sequencing of hotspots and coding regions from 36 genes, as well as
intronic coverage for detection of ALK/ROS1 fusions in plasma cfDNA assays to detect
driver and resistance mutations, compared with plasma droplet digital PCR and tumor
genotype for diagnostic accuracy. Blinded analysis in this study demonstrated the capacity
of amplicon-based plasma next-generation sequencing (NGS) to detect a full range of
targetable genotypes in NSCLC with high accuracy.46 Almdovar et al48 recently reported a
longitudinal plasma cfDNA genotyping analysis of patients with SCLC, in which they aimed
to gain dynamic insights into treatment efficacy and disease relapse with 140 plasma
samples from 27 patients over a 26-month blood sample collection period. The assay detects
single nucleotide variants, copy number variation, and indels in 14 genes that are frequently
mutated in SCLC, including TP53, RB1, BRAF, KIT, NOTCH1/2/3/4, PIK3CA, PTEN,
FGFR1, MYC, MYCL1, and MYCN. Results showed that disease-associated mutations
were detected in 85% of cases, with TP53 (70%) and RB1 (52%) being the most common,
which is consistent with previous data from tissue analysis. Hence, the study demonstrated
that cfDNA genotyping analysis using targeted sequencing in SCLC is feasible, with the
results matching relatively well with those obtained from tissue analysis. It also appears that
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genotypic alterations detected by longitudinal cfDNA analysis might be predictive of clinical
or radiographic progression. cfDNA genotyping analysis may also be useful in detecting
minimal residual disease after treatments. That said, in this particular aggressive disease
category of SCLC, the utility of longitudinal cfDNA analysis in clinical practice can be
considered debatable. It is doubtful, at least for now, whether chemoresistance detection can
meaningfully impact clinical outcomes, given the very limited salvage treatment options
available, especially in extensive disease.

Author Manuscript

Exciting reports highlighting the promising potential of ctDNA profiling in liquid biopsy as
a tool for early cancer detection have appeared in the last few years. Abbosh et al49 used a
tumor-specific phylogenetic approach to profile the ctDNA of the first 100 participants
enrolled in the TRACERx (Tracking Non-Small-Cell Lung Cancer Evolution Through
Therapy [Rx]) study. They showed that a phylogenetic ctDNA profiling method tracked the
subclonal nature of lung cancer relapse and metastasis, providing a new approach for
ctDNA-driven therapeutic studies.49 Most recently, a new liquid biopsy assay platform,
CancerSEEK, sought to detect eight common types of cancer (i.e., esophagus, breast, lung,
stomach, liver, pancreas, colorectum, and ovary) through assessment of the levels of
circulating proteins and mutations in cfDNA.50,51 The authors reported a positive result of
about 70% (median) across the eight common cancer types among more than 1,000 patients.
The specificity was greater than 99%, and only 7 of 812 healthy controls had a positive score
on the CancerSEEK test. Currently, there are numerous active ongoing clinical studies
investigating the utilities of CTCs and cfDNA/ctDNA in human cancers (Table 1).

Author Manuscript

Blood proteomics.—Beyond DNA in the blood compartment, soluble protein and
peptides represent other biomolecular analytes that can be measured for clinical diagnostics
purposes. Technologically, it is more difficult to identify and measure individual protein
peptides beyond proteomics profiling for peptide signatures, compared with the genomics
platforms. As a result, advances in liquid proteomics biopsies trail behind liquid genomics,
especially the ctDNA biopsy for clinical/translational applications. Nonetheless, steady
progress has been made in this area over the past 1 to 2 decades.

Author Manuscript

Blood-based proteomic biomarker assays have recently met with notable milestones in
bedside adoption. A blood-based proteomics biomarker signature test, VeriStrat (Biodesix,
Boulder, CO), was developed using matrix-assisted laser desorption ionization time-of-flight
mass spectrometry (MS)52–54 for patients with wild-type EGFR lung cancer to stratify them
into a “good signature” group and a “poor signature” group. Patients with a good signature
are predicted to potentially derive benefits from platinum-based chemotherapy, single-agent
chemotherapy, or EGFR-TKI therapy. Conversely, patients with a poor signature are
predicted to be less likely to respond to platinum-based therapy and single-agent
chemotherapy and not likely to respond to EGFR-TKI. A phase III study to test the
predictive power of the VeriStrat test in the second-line therapy of patients with advanced
NSCLC was published in 2014.54 The investigators analyzed 129 patients (91%) randomly
assigned to the chemotherapy treatment group and 134 patients (94%) randomly assigned to
the erlotinib treatment group. A significant interaction between treatment and proteomic
classification was found. Patients with a poor VeriStrat proteomic test classification had
worse survival with erlotinib than chemotherapy (HR 1.72; 95% Cl, 1.08–2.74; p = .022).
Am Soc Clin Oncol Educ Book. Author manuscript; available in PMC 2019 May 23.
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There was no overall survival difference between treatments for patients with a good
proteomic test classification. The authors concluded that VeriStrat serum protein test status
is predictive of differential benefit in overall survival for erlotinib versus chemotherapy in
the second-line setting. Patients classified as likely to have a poor signature had better
outcomes with chemotherapy than erlotinib.

Author Manuscript

More recently, the VeriStrat serum protein test was evaluated among patients with advanced
squamous cell NSCLC treated with second-line afatinib or erlotinib in the phase III LUXLung 8 study of 795 patients.55 Pretreatment VeriStrat status was correlated with overall
survival, progression-free survival, and other endpoints. The investigators found that a good
VeriStrat classification was strongly associated with favorable outcomes with either afatinib
or erlotinib compared with a poor VeriStrat classification. Multivariate analysis showed that
VeriStrat was an independent predictor of overall survival for afatinib-treated patients,
regardless of Eastern Cooperative Oncology Group performance status or best response to
first-line chemotherapy. For patients with a good VeriStrat classification, survival outcomes
were found to be better with afatinib treatment (HR 0.79; 95% Cl, 0.63–0.98) than with
erlotinib treatment. A recent questionnaire study reported that the serum-based proteomic
test impacted treatment recommendations among physicians ordering the VeriStrat test.56

Author Manuscript

Blood metabolomics.—Although the development of molecular cancer diagnostics has
been emphasized in the fields of genomics, transcriptomics, and proteomics in the past
decade, there is renewed recognition and dedicated research effort in the area of cancer
metabolism and metabolomics. With advances in and wider adoption of MS-based profiling
technology, blood serum or plasma-based metabolite measurements can now be readily
achieved, both in targeted individual metabolite measurement and in global metabolomics
profiling. A number of studies focusing on blood-based metabolite assays for lung cancer
diagnostics have been published over the past decade.57–63 Nonetheless, the platforms
studied primarily remain investigative in nature and are not yet ready for clinical
applications. Prospective validation studies are mostly still lacking. Various studies have also
produced differing and sometimes conflicting metabolite identities and/or quantities,
probably at least partly as a result of methodologic and instrumentation differences, making
it difficult to draw more sound conclusions on the platform’s utility. A deeper understanding
of and insight into the interrelationship between normal and cancer metabolic pathways and
the correlations with metabolites produced would certainly help the interpretation of future
cancer metabolites/metabolomics biomarker research.

Author Manuscript

With the advances in MS instrumentation and computational bioinformatics methods, there
has been a steep increase in literature reports in recent years on the use of blood-based
global metabolomics profiling in various human cancers, ranging from cancer risk
evaluation,64 diagnostics for genotype-phenotype (e.g., SRCAl-mutated breast cancer),65
early cancer detection,66,67 and surveillance of cancer recurrence/progression.68

SALIVA BIOPSY
The utility of DNA extracted from saliva samples for genome-wide molecular research
platforms has been studied and found to be feasible,69 especially compared with blood
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DNA.70 A recent pilot study showed that a salivary DNA tumor-suppressor methylation
gene panel could have the potential to detect early-stage tumors for patients with HPVnegative head and neck squamous cell carcinoma. Methylation levels of patients with HPVpositive head and neck squamous cell carcinoma were deregulated by HPV infection.71
In 2014, a novel platform of electric field-induced release and measurement was developed
to detect EGFR mutations directly in body fluids with a multiplexable electrochemical
sensor. The investigators demonstrated that EGFR mutations could be detected in the saliva
of patients with NSCLC, with an area under the curve of 0.94 for Del19 and 0.90 for L858R.
72 In 2016, Pu et al73 used electric field-induced release and measurement and detected the
classic oncogenic EGFR mutations in the saliva plasma ctDNA samples of 17 patients with
lung adenocarcinoma. They reported complete concordance of the assay results, with an area
under the curve of 1.0.

Author Manuscript

CEREBROSPINAL FLUID BIOPSY
The brain and the central nervous system (CNS) represent a sanctuary where tumor cells
residing there could be protected from systemic therapy due to the blood-brain barrier as a
therapeutic obstacle. Similarly, ctDNA from primary CNS tumors is rarely detected in the
systemic blood circulation, unlike in other visceral primary solid tumors. Hence, the
cerebrospinal fluid (CSF) compartment represents a unique and potentially highly
informative space for molecular diagnostics development.

Author Manuscript

In 2006, Choong et al74 identified CTCs in the CSF of a patient with lung cancer with
advanced FGFR-mutant disease and symptomatic leptomeningeal metastases that had
progressed during therapy. They further demonstrated the feasibility of detecting a unique
EGFR gene mutation (E884K) In the laser-capture microdissected CSF CTCs responsible
for drug resistance against erlotinib but hypersensitization to gefitinib.75 In addition, CSF
cfDNA from patients with cancer was adopted for quantitative detection of cancer gene
mutations using digital PCR and targeted amplicon sequencing methods, compared with
collected plasma, for seven patients with solid brain tumors. The authors identified seven
somatic mutations from the CSF of a patient with leptomeningeal disease through the use of
cancer panel sequencing, which was also in concordance with genotype testing on the
corresponding primary tumor biopsy.76

Author Manuscript

More recently, Pentsova et al77 used NGS of 341 cancer-associated genes in the CSF of 53
patients with known or suspected CNS metastatic disease from solid malignancies. They
reported detection of somatic genomic alterations for 63% (20 of 32) of patients with solid
tumor CNS metastases, 50% (6 of 12) of patients with primary brain tumors, and 0% (0 of 9)
of patients without CNS involvement by cancer. CSF tumor-associated cfDNA was also
detected from primary CNS tumors (medulloblastomas, ependymomas, and high-grade
gliomas) abutting a CSF space or cortical surface.78
A recent study showed that the sensitivity of comprehensive NGS for somatic mutation
detection of the CNS ctDNA was higher than that using plasma ctDNA for patients with
CNS tumors (58% vs. 0%). For patients with abundant visceral disease, the sensitivity of
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CNS DNA and plasma DNA was comparable (60.5% vs. 55.5%). Moreover, the results also
showed that the CSF ctDNA derived from CNS tumors was more abundant than that in the
plasma. Importantly, the authors further demonstrated that CSF ctDNA levels fluctuated
longitudinally in a time-dependent and in parallel fashion mirroring the changes in brain
tumor burden.79 In another recent study, LI et al80 detected CSF-associated ctDNA using
droplet digital PCR for a patient with BRAF-V600E-positive melanoma to monitor the
response of metastatic leptomeningeal disease treated with whole brain radiotherapy and
BRAF-specific inhibitors. Using nine CSF samples over 6 months, the mutant CSF ctDNA
fractions were found to match well with the disease burden and clinical course under
treatment, and they corresponded well with the treatment response. Whole-exome
sequencing (WES) revealed a canonical cancer gene mutation, PTEN-R130*, in CSF ctDNA
of a patient with leptomeningeal disease both before treatment response and after disease
relapse.80 In addition, similar mutational profiles were found in the cellular and ctDNA
(cfDNA), supporting the notion that the ctDNA is a derivative and representative of
leptomeningeal disease cells. Hence, CSF ctDNA represents a novel molecular diagnostics
platform for use as (1) a method for genomic biomarkers and actionable mutation detection,
(2) a complementary tool to diagnose CNS tumors and leptomeningeal carcinomatosis, and
(3) a monitoring tool for disease burden and treatment progress in CNS malignancies.

URINE BIOPSY
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Urine is an attractive body fluid compartment for cfDNA molecular assays for cancer
diagnostics. The urine biopsy is truly noninvasive, without even the need for a needle
phlebotomy as in the case of a blood biopsy. Patients can collect their own urine samples at
home or in the hospital or clinic. Furthermore, serial sample collection is not difficult or
risky for patients and is usually not restricted by patient performance status or disease
conditions. Attempts to achieve molecular diagnostics in urine samples for genitourinary
cancers date back decades. In 1991, p53 gene mutations were first Identified In the urine
sediment of patients with bladder cancer.81 Subsequently, a number of reports followed that
demonstrated various gene mutations (e.g., FGFR mutations) identified in the urinary
ctDNA extracted from patients with genitourinary cancer.82,83 Besides gene mutations, urine
can be used as a source for epigenetic alteration assays. In 1989, a three-marker DNA hyperand hypomethylation panel (IRAK3, L1-MET, and SOX1) in urine sediment was reported to
accurately predict bladder cancer recurrence among 80% of patients, which compared
favorably to urine cytology (35%) and cystoscopy (15%).84 Today, it is understood that there
are two different fractions of ctDNA in the urine. First, ctDNA can be derived from the
urinary tract and associated endothelial cells as high molecular weight DNA. Second,
ctDNA can be originated as low molecular weight DNA from ctDNA fragments that were
excreted into urine during the process of renal glomerular filtration. Studies recently
reported that urinary ctDNA can be detected in nonurothelial cancers as well, such as in liver
cancer with TP53 mutations85 and in NSCLC with EGFR mutations.86,87
One of the challenges in urinary ctDNA molecular detection and diagnostic assays is related
to the fact that not only is urinary ctDNA highly fragmented but it is also present with a very
low abundance (< 0.01%) among the background of wild-type cfDNA. This is similar to the
technical challenges experienced in the field of plasma-based blood biopsy molecular
Am Soc Clin Oncol Educ Book. Author manuscript; available in PMC 2019 May 23.
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assays. Despite these technical difficulties, a sensitive and quantitative detection of EGFR,
BRAF, and KRAS mutations in urine was reported to be achievable using short-footprint
mutation enrichment PCR coupled with an NGS approach.87–89 Using this platform,
reported limits of detection for EGFR mutations L858R, Del19, and T790M in urine or
plasma were 0.006%, 0.006%, and 0.01%, respectively, which compare favorably with the
U.S. Food and Drug Administration–approved Cobas EGFR Mutation Test (limit of
detection ≥ 0.2%; Roche Molecular Diagnostics, Pleasanton, CA).87,90,91
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Chen et al86 reported dynamic tracking of EGFR mutations among patients with NSCLC
using urinary ctDNA detection in a serial monitoring trial of patients receiving precision
TKIs. Their results showed a concordance in the quantity of urinary cfDNA and plasma
cfDNA at baseline as well as in ctDNA decline during treatment.86 Using the short-footprint
mutation enrichment NGS assay, Reckamp et al87 reported detection of oncogenic EGFR
mutations and T790M resistance mutation in the urine and plasma of patients with NSCLC
with comparable sensitivity. The group retrospectively analyzed samples from 63 patients
with advanced NSCLC enrolled in TIGER-X, a phase l/ll study of rociletinib (a thirdgeneration EGFR-TKI) focusing on the most common, recurrent EGFR hotspot mutations,
using the mutation enrichment PCR/NGS platform. The sensitivity of EGFR mutation
detection in urine was up to 80% to 93% in samples that met recommended urine volumes
(90–100 mL). A high specificity of 94% to 100% was attained with the EGFR urine testing
assay, as determined using samples from healthy volunteers. Further evaluation of the
concordance between urine and tissue EGFR T790M results in an expanded data set yielded
a somewhat improved positive percentage agreement of 81% and equivalence in the rate of
detection compared with plasma. The negative percentage agreement was 31%, raising the
issue of discrepancies between tissue and liquid biopsy results likely as a result of tumor
sampling errors and intratumoral heterogeneity. Recently, some investigators proposed a
patient treatment paradigm in EGFR-mutant NSCLC, in which plasma genotyping serves as
the reflex test upon progression on first-generation FGFft-TKIs to ameliorate the challenges
associated with repeat tumor tissue biopsies. A negative ctDNA assay result would prompt
tumor tissue rebiopsy and genotyping. Most recent data on the clinical relevance and validity
of urine ctDNA molecular testing suggest that it could be included in the molecular
diagnostics model to combine urine- and plasma-based genotyping assays to precede tumor
tissue biopsies.

STOOL BIOPSY

Author Manuscript

Potential use of stool samples for molecular detection of colorectal cancers has long been
sought as a means to achieve early detection of malignancies. Reports of detecting
oncogenes in patient stool samples date back to 1992, when Sidransky et al92 identified RAS
oncogene mutations in the stool of patients with curable-stage colorectal cancer. KRAS
represents one of the most well-known and well-characterized oncogenes in human cancers,
which can be somatically mutated within several hotspots (codons 12, 13, and 61) in a
variety of cancer types. As such, much effort has centered on achieving early cancer
detection by assaying for the presence of KRAS mutations in human tumors such as those in
the colon, rectum, lung, and pancreas.93 Besides stool samples, molecular diagnostics tests
using mutated KRAS detection have been reported in pancreatic and duodenal lavage fluid,
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sputum, and lavage samples from patients with colorectal and lung cancers. In addition to
KRAS, early studies have also detected adenomatous polyposis coli mutations in stool DNA
from patients with colorectal tumors, raising the promise for noninvasive early detection of
the disease.94 Both proximal and distal colorectal cancers can be well detected similarly
using stool DNA molecular assays.

Author Manuscript

Although colonoscopy screening is proven to be effective in the early detection of colorectal
cancer and to impact survival rates, target population compliance remains low, partly
because of the invasive and unpleasant nature of the procedure. Stool DNA detection has
been found to notably improve sensitivity compared with fecal occult blood tests. Compared
with colonoscopy screening, stool DNA detection is quite attractive because of its
noninvasive and convenient nature. In 2014, the U.S. Food and Drug Administration
approved Cologuard (Exact Sciences Corp., Madison, Wl), a multitarget stool DNA test for
colorectal cancer screening for average-risk adults age 50 and older.95 The interval testing
frequency was determined to be every 3 years with adequate Medicare coverage. Effective
July 1, 2017, United Healthcare began covering Cologuard as a colon cancer screening test.
Cologuard incorporates molecular assays for aberrantly methylated BMP3 and NDRG4 gene
promoter regions, mutant KRAS, and β-actin as well as an immunochemical assay for
human hemoglobin. Cologuard is based on a study by Imperiale et al,96 which demonstrated
notably improved sensitivity for colorectal cancer detection compared with the fecal
immunochemical test. Although Cologuard is a one-time screening stool DNA test that
detects 92% of cases of colorectal cancer among asymptomatic average-risk persons
compared with 74% with the fecal immunochemical test, Cologuard was able to detect less
than one-half of advanced precancerous lesions (42% sensitivity) and produced a substantial
number of false-positive results.

Author Manuscript

Further molecular testing methods are in development to improve the detection of epigenetic
changes (e.g., DNA methylation in plasma and stool DNA samples).97 Li et al97 developed a
methyl-BEAMing (Beads, Emulsion, Amplification, Magnetics-ing) technology to enable
absolute quantification of the number of methylated molecules in a biologic sample,
achieving highly sensitive enumeration of as few as 1 methylated molecule in approximately
5,000 unmethylated molecules in DNA from plasma or stool samples. Digital quantification
of rare methylation events in clinical samples could have translational applications in cancer
diagnostic and prognostic uses as well as in preclinical evaluation of novel epigenetic
biomarkers.

EMERGING NEW PLATFORMS
Author Manuscript

Liquid Biopsy
Exosome profiling.—Peripheral blood exosome (microvesicle) profiling is an area of
exciting and potentially impactful liquid biopsy research that has emerged in recent years.
Exosomes were first described in 1983 by Pan and Johnstone98 as a subclass of extracellular
nonvesicles with a 40- to 150-nm diameter membrane with an endocytic origin that contain
biomolecules of nucleic acids (including DNA, mRNAs, and microRNAs), proteins, and
lipids and nucleic acids that are released by all cell types, including cancer cells. Exosomes
are believed in be involved in intercellular communication in physiologic and malignant
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conditions. Cancerous exosomes carry a cargo load of malignant bioinformation in the form
of nucleic acids, proteins, and lipids that are capable of reprogramming the recipient cells.
Recently, exosomes have been highlighted as putative transforming agents in malignancies,
having a potentially causative role in major steps or processes of tumor progression,
including immune response modulation, tumor microenvironment reprogramming, invasion,
and metastasis.99–103

Author Manuscript
Author Manuscript

Of interest, recent studies suggested that exosomal microRNAs may be involved in disease
progression, potentially via stimulating angiogenesis and promoting metastasis.104 Most
recently, another new study demonstrated for the first time that before tumor cells acquire
metastatic capacity, the tumors alert the host immune system continuously by generating
exosomes, which carry triggers of innate immune responses such as the reported pigment
epithelium-derived factor.105 Another recent study106 demonstrated that certain microRNAs
(e.g., miR-196a and miR-1246) are specifically enriched in pancreatic cancer cell–derived
exosomes and are present in the plasma exosome at elevated levels among patients with
localized pancreatic cancer. Fang et al107 recently reported that tumor-derived exosomal
miR-1247–3p showed positive correlation with lung metastasis for patients with
hepatocellular carcinoma and could convert fibroblasts to cancer-associated fibroblasts by
decreasing B4GALT3, which would then activate the β1-integrin/nuclear factor-κΒ signaling
pathway in the lung premetastatic niche from hepatocellular cancer. Furthermore, cancerassociated fibroblasts displayed increased secretion of interleukin-6 and interleukin-8,
resulting in the promotion of cancer stermness, EMT, chemoresistance, and tumorigenicity
of tumor cells. Most recently, a novel liquid biopsy platform that can achieve immense
coverage of system-wide, native biomolecules was developed for plasma exome profiling for
patients with cancer using a next-generation systems biology approach.108 Domenyuk et
al108 used this novel approach (named adaptive dynamic artificial poly-ligand targeting,
which embodies an enriched library of single-stranded oli-godeoxynucleotides to profile
complex biologic samples) as a highly specific profiling tool to distinguish women with or
without breast cancer based on circulating blood exosomes. The study achieved an area
under the curve of 0.73 when healthy donors were compared with patients with biopsypositive breast cancer.

Author Manuscript

Cancer immunotherapy.—Clinically relevant and actionable predictive biomarkers for
cancer immunotherapy remain an area of huge unmet need. Since the arrival of anti-CTLA-4
and anti-PD-1/PD-L1 cancer immunotherapy and its clinical fruition with various U.S. Food
and Drug Administration approvals granted for its use as standard-of-care cancer treatment
in multiple cancer types, a few genomic and tissue biomarkers have been validated and
approved for cancer immunotherapeutics. These include tumoral PD-L1 expression levels
(as companion diagnostics for pembrolizumab and as complementary diagnostics for
nivolumab and atezolizumab)109–110 and, more recently, microsatellite instability status
(with high microsatellite instability as a tumor type agnostic biomarker for pembrolizumab).
111 Furthermore, strong evidence of tumor mutational load (or mutational burden) has been
found to support its use as a predictive immuno-oncology biomarker.112–114 Nonetheless,
alternative means of achieving immunotherapy biomarkers have been keenly sought in
recent years, at least in part because of the practical issues surrounding invasive tumor tissue
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biopsies, potential sampling errors in needle biopsies especially in the setting of tumor
heterogeneity, and limitations in attempting repeat tissue biopsies during therapies. Again,
liquid biopsy represents one of the top priorities in the quest for optimal noninvasive
immuno-oncology biomarkers.115

Author Manuscript

Again, ctDNA in liquid biopsy serves as a source for a more comprehensive representation
of the tumor genomic status in immuno-oncology therapy and thus contributes as a potential
substrate for immuno-oncology treatment biomarkers. Koeppel et al116 reported a study in
which tumor mutation load was assayed from cfDNA (i.e., ctDNA) using WES, rather than
in tumor tissue DNA. They performed WES on cfDNA from 32 patients with different types
of metastatic cancer in the MOSCATO 01 and/or MATCHR molecular triage trials
(NCT01566019 and NCT02517892, respectively). WES mutation detection sensitivity was
92% in cfDNAs compared with targeted sequencing, whereas mutation detection sensitivity
was 53% when cfDNA-WES was compared with tissue DNA-WES. For samples in which
the presence of tumor DNA was confirmed in cfDNA, the tumor mutation load from the
liquid biopsy was correlated with the tumor biopsy. In another study, Goldberg et al117
enrolled 28 patients with metastatic NSCLC undergoing Immunotherapy treatment and
compared ctDNA level changes with radiographic tumor size and survival outcomes. They
found that the median time to Initial response was 24.5 days by ctDNA versus 72.5 days by
imaging evaluation. ctDNA response was associated with superior progressionfree survival
(HR 0.29; 95% Cl, 0.09–0.89; p = .03) and superior overall survival (HR 0.17; 95% Cl,
0.05–0.62; p = .007). A decline in ctDNA levels is therefore considered to be an early
marker of therapeutic efficacy, predicting greater prolonged survival for patients with
NSCLC treated with immune checkpoint Inhibitors.

Author Manuscript

Khagl et al118 interrogated for hypermutated ctDNA as mutational burden to correlate with
the response to checkpoint Immunotherapy In a diverse group of cancers. Significant
Improvement in PFS and overall survival was found to be associated with high versus low
alteration number in variants of unknown significance (VUS > 3 alterations vs. VUS ≤ 3
alterations). These results provide support for further investigations into the ctDNA genomic
landscape as immunotherapy predictive biomarkers. Besides ctDNA, isolated CTCs from
patients undergoing immuno-oncology therapy were also used for biomarker interrogation.
Boffa et al119 studied the cellular expression of PD-L1 In the peripheral blood circulating
cells and associated with poorer survival. In a Cox model analysis adjusting for stage, high
PD-L1(+) cell burden was a significant predictor of mortality (HR 3.85; 95% Cl, 1.64–9.09;
p = .002).

Author Manuscript

Finally, novel emerging technology platforms such as serum proteomics and immune
repertoire NGS also enable promising research to be conducted among patients undergoing
immuno-oncology therapy for biomarker analysis.120,121 Although these novel assay
platforms are promising, more validation studies and larger prospective analyses are needed
before they could be translated to clinical use.
Breath Biopsy/Volatile Organic Compound Profiling
Exhaled human breath is known to contain at least a few thousand volatile organic
compounds (VOCs) and can potentially be exploited as a VOC biomarker in breath biopsies
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for human disease diagnostics, including cancers.122–124 In general, VOCs are organic
chemicals that possess a high vapor pressure at ordinary room temperature, resulting in a
low boiling point. Thus, large numbers of the molecules would evaporate from the liquid or
solid phases of the compound as “volatile” substances entering into the surrounding air
space. In fact, VOCs are ubiquitous, numerous, and varied, including both naturally
occurring as well as human-made chemical compounds. In the human body, VOCs are
thought to be mainly blood borne and thus could enable the monitoring or diagnosis of
disease processes in the body beyond just the oropharyngeaI cavities and Iungs.123 Recent
advances in MS-based assay platforms have brought about more modern studies in cancer
diagnostics using nonvolatile metabolomics profiling, evaluating the spectral landscapes of
metabolites in patient tissues or blood as biomarkers. Beyond these nonvolatile metabolites,
VOCs can now also be identified and measured in various headspace gas phases of human
tissues, blood, and urine and even in exhaled breath. An emerging body of literature over the
past decades has suggested that the feasibility and promise of VOC profiling or
fingerprinting could be an attractive noninvasive cancer diagnostic in the future.125

Author Manuscript
Author Manuscript

Pilot and proof-of-concept studies in the lung cancer field have increasingly been published
in recent years using VOC profiling with gas chromatography/MS and various chemical
sensor matrices including microfluidic chip sensors. Hence, the spectrum and concentrations
of VOCs in breath samples can be captured with the sensors as correlates of the broad
chemical constitution of the biospecimen without the absolute need for the identities of the
specific VOC components. Cancer is now more regularly classified through the prism of the
genomic lens with genomic alterations guiding precision therapeutics. This is particularly
true as seen in genomic discoveries in recent years in lung adenocarcinoma. Peled et al126
previously reported a proof-of-concept in vitro pilot study using tumor cell VOC detection
with nanomaterial-based sensors to profile genetic mutations of lung cancer cells (namely,
EGFR mutations, KRAS mutations, and EML4-ALK fusion). Breath analysis has also been
adopted for the study of pulmonary nodules and for identification and characterization of
lung cancer. Mazzone et al127 reported identification of exhaled breath VOC biosignatures of
lung cancer using a colorimetric VOC sensor array in a study cohort with 229 participants
(92 patients with lung cancer and 137 controls). The authors suggested optimizing the breath
biosignature accuracy by incorporating clinical parameters (e.g., risk factors and histology).
Peled et al128 reported the use of VOC profiling breath analysis to discriminate benign from
malignant pulmonary nodules in a high-risk cohort of 19 patients with benign disease and 53
with malignant disease with similar smoking histories and comorbidities. More recently,
Nardi-Agmon et al129 further reported the use of noninvasive breath biosignatures, as
determined by gas chromatography/MS and a nanomaterial-based sensor array, to correlate
with and monitor treatment response in advanced lung cancer in a small study of 39 patients
and 143 collected breath samples. These applications could potentially have a notable
impact on clinical decision making and therapeutics determination.
Various devices and technologies designed to detect VOCs for cancer diagnostics using not
only exhaled breath but also other noninvasive body substrates such as urine are currently
available. In addition to the more routine application of gas chromatography/MS used in
electronic nose technology (eNose, Zutphen, Netherlands) with arrays of nonselective
chemical sensors, other competing technologies are emerging such as the field asymmetric
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ion mobility spectrometry microchip.130 This microchip platform is a variant of Ion mobility
spectrometry,130 a method of distinguishing charged gaseous molecules according to
differences in the speed at which they move through a buffer gas under the Influence of an
oscillating electric field. It is claimed to have improved advantages in overcoming sample
stability and sensitivity issues and in data analysis. VOC detection at low parts per billion
(and in some cases, parts per trillion) levels is feasible in the field asymmetric ion mobility
spectrometry microchip platform, enabling it to be well suited not only for clinical sample
assaying but also for use as a potential future point-of-care measurement in a portable and
convenient fashion. Another new exciting technology in development is the Nanobeak
Sensor (Nanobeak Inc., New York, NY), which converges nanoelectronics, bioinformatics,
and wire-less technology to achieve a mobile point-of-care screening application based on
chemical VOC sensing within a small Bluetooth device. The Nanobeak technology uses
carbon nanotubes to detect VOCs with the invention originated from the National
Aeronautics and Space Administration when It launched the nanosensor into orbit in 2007 to
test and determine that It works well in outer space. Currently, a number of pilot clinical
studies using these new breath biopsy technologies for cancer diagnostics are ongoing or are
being planned (NCT02888366, NCT02781857, NCT02123030, NCT03275688,
NCT01292369, NCT01386203, and NCT02612532).

CONCLUSION

Author Manuscript
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In recent years, we have witnessed a revolutionary advancement in cancer medicine among
the whole spectrum of cancer genomics, molecular genomics diagnostics, technological
platform innovations, and cancer therapeutics. As a result, we have seen an unprecedented
pace of progress in the expansion of cancer diagnostics on tumor tissues as well as beyond
tissues in novel noninvasive molecular assays, in parallel with the ever-growing list of cancer
therapeutics such as precision therapies and immunotherapeutic agents. Noninvasive
molecular diagnostics beyond tissues have already found clinical utility and application
particularly in the area of cfDNA/ctDNA genotyping/genomic profiling as a blood biopsy
(liquid biopsy) technique. They have also been increasingly applied in longitudinal
monitoring of therapy for early disease detection and in therapeutic response-resistance
monitoring. Various other promising noninvasive cancer diagnostics assay platforms also
include saliva biopsy, urine biopsy, stool biopsy, CSF biopsy, other forms of blood biopsy
beyond cfDNA/ctDNA (e.g., proteomics and metabolomics), and even breath biopsy for
VOC measurement. It is Important to emphasize the crucial significance of committing
appropriate resources and applying rigorous study designs for validating these promising
assay platforms in large-scale prospective clinical studies to bring them to fruition.
Moreover, rigorous scientific scrutiny of the various assay platforms remains indispensable
to discern between hype and reality when assessing each novel molecular diagnostics
platform that emerges.
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•

Nontissue-based next-generation novel noninvasive molecular diagnostics
platforms have been emerging and expanding in clinical applications to match
the revolution in cancer precision medicine and immunotherapies.

•

Novel noninvasive molecular diagnostics platforms have increasingly been
applied to serial longitudinal biopsies to better monitor and interrogate tumor
progression and evolution under therapies.

•

Next-generation novel noninvasive molecular diagnostics platforms include
liquid biopsies, salivary biopsies, stool and urine biopsies, and breath
biopsies.

•

The emergence of the cancer immunotherapy revolution poses unprecedented
promise in cancer treatments but also extraordinary challenges in the need for
novel and validated cancer diagnostics and biomarkers to optimize the
therapeutic impact.

•

A number of novel noninvasive molecular diagnostics need large-scale
prospective validation studies to ascertain their role in bedside molecular
diagnostics applications.
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FIGURE 1.

Novel Noninvasive Cancer Molecular Diagnostics Platforms Beyond Tissues
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